Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Peptide therapy with MOTS-c aims to replenish these levels, effectively turning back the clock on your cellular metabolism
Immunovant Sector: Pharmaceuticals and biotechnology (autoimmune and immunology therapeutics) HQ: 320 W 37th St., New York, NY Year Founded: 2018 Key Leaders: Eric Venker, MD, PharmD, CEO Number of Employees: 362 Stage: Public Financial Snapshot: $3.83 billion Notable Investors: SG Americas Securities, Roivant Sciences, RTW Investments, and BVF Partners Key Products: Immunovant is developing Batoclimab, an FcRn-targeting monoclonal antibody for autoimmune diseases (MG, TED, Graves disease), which is in Phase 3 registrational trials
Governments and health authorities are increasingly recognizing the importance of GLP-1 therapies in managing chronic diseases, leading to expedited approval processes for new drugs
GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon)are prescribed for type 2 diabetes management and, in some formulations, for weight management in adults with obesity or overweight with comorbidities
10.1152/ajpendo.1997.273.5.E981 17
US$ 26.98
US$ 23.88
US$ 26.74
US$ 27.07
US$ 20.15
US$ 26.79
US$ 23.38
US$ 25.16
US$ 21.38
US$ 21.39
US$ 26.06
